Table 1.
Patient characteristics (N=315)
| Median (range) | |
|---|---|
| Recipient age | 57 (19-74) |
| Number (%) | |
| Gender | |
| Male | 196 (62) |
| Female | 119 (38) |
| Race | |
| European American | 307 (98) |
| Other | 8 (2) |
| Diagnosis | |
| AML | 131 (42) |
| MDS/MPD | 71 (23) |
| ALL | 38 (12) |
| NHL/HL | 46 (15) |
| Other | 29 (9) |
| Recipient / donor CMV serostatus | |
| Negative / negative pairs | 121 (38) |
| Positive / negative pairs | 89 (28) |
| Positive / positive pairs | 57 (18) |
| Negative / positive pairs | 48 (15) |
| KPS at time of HCT | |
| ≤80 | 262 (83) |
| ≥90 | 53 (17) |
| Donor HLA matching | |
| MRD | 120 (38) |
| MUD | 187 (59) |
| MMUD | 8 (2) |
| Number of HLA alleles for which Dextramers were available | |
| 1 | 111 (35) |
| 2 | 90 (29) |
| 3 | 83 (26) |
| 4 | 22 (7) |
| 5 | 9 (3) |
| Status at HCT | |
| CR | 163 (52) |
| Not in CR | 152 (48) |
| HCT regimen | |
| Reduced intensity conditioning | 253 (80) |
| Myeloablative | 62 (20) |
| Acute GvHD prophylaxis regimen | |
| FK MMF CY | 2 (1) |
| FK MTX | 18 (6) |
| FK MTX MMF | 288 (91) |
| FK, FK MMF, FK SIR | 7 (2) |
Abbreviations: AML – acute myeloid leukemia, ALL – acute lymphoblastic leukemia, CMV – cytomegalovirus, CR – complete remission, FK – tacrolimus, HCT – hematopoietic cell transplantation, HL – Hodgkin lymphoma, HLA – human leukocyte antigen, KPS – Karnofsky performance status, MDS – myelodysplastic syndrome, MMF – mycophenolate mofetil, MMUD – HLA mismatched unrelated donor, MPD – myeloproliferative disease, MRD – HLA matched related donor, MTX – methotrexate, MUD – HLA matched unrelated donor, N – number, NHL – non-Hodgkin lymphoma, SIR - sirolimus